24/7 Market News Snapshot 28 October, 2024 – INmune Bio Inc. Common stock (NASDAQ:INMB)

October 28, 2024

DENVER, Colo., 28 October, 2024 (247marketnews.com) – (NASDAQ:INMB) are discussed in this article.
INmune Bio Inc. (INMB) has garnered significant investor attention today with its shares opening at $5.65 and currently trading at $6.075, marking an impressive upward shift of approximately 12.08% from the previous close of $5.42. The trading volume has reached 510.57K, indicating robust interest among investors. This surge has allowed the stock to surpass key resistance levels, potentially drawing in further buyers. Observers are advised to keep a close watch on this momentum, as maintaining volume above the average could herald a continuation of the upward trend. Upcoming earnings reports or related news could play a crucial role in influencing INMB’s performance amid the current market volatility.

Simultaneously, INmune Bio is positioning itself at the forefront of cognitive assessment in Alzheimer’s research. The company has announced an upcoming webinar set for November 7, 2024, at 1 PM ET, focusing on the Early and Mild Alzheimer’s Cognitive Composite (EMACC). This session, titled “Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials,” will delve into the development of EMACC and its significance in evaluating cognitive transitions in early-stage Alzheimer’s patients.

The panel will feature prominent figures, including Dr. Judith Jaeger, President of CognitionMetrics, and Dr. Sarah Barnum, VP of CNS Drug Development at INmune Bio. Participants can expect insights into the regulatory dynamics involved in Alzheimer’s drug development, focusing on the importance of measuring cognitive change rather than just assessing disease stages.

Additionally, INmune Bio will showcase a poster at the Clinical Trial in Alzheimer’s Disease (CTAD) conference, presenting critical findings on the validation of EMACC in Phase II clinical trials. As the company progresses with its global, randomized Phase II trial using XPro™ aimed at neuroinflamed patients, it is committed to enhancing patient care and streamlining Alzheimer’s clinical research methodologies.

Related news for (INMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.